Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.43 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574317 | 0.91 | IDO1 (0.43) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL1154758 | 0.86 | IDO1 (0.50) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL29493203 | 0.86 | IDO1 (0.50) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL701343 | 0.86 | CYP2A6 (0.48) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL7424709 | 0.83 | IDO1 (0.41) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL7376868 | 0.83 | HTR2A (0.46) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL14625313 | 0.78 | CYP2A6 (0.43) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL21741544 | 0.78 | CYP2A6 (0.43) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL10537631 | 0.78 | IDO1 (0.43) | IDO1HTTHIF1ACYP3A4MAPT | |
| SCHEMBL8137835 | 0.78 | PSEN1 (0.47) | IDO1HTTHIF1ACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| CN-103833827-B | A kind of amides compound, its pharmaceutical composition, preparation method and application | 上海医药工业研究院 | 2016-08-03 | — | — | CN | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| CN-103833827-A | Amide compounds, medicine compositions, preparation method and application thereof | SHANGHAI INST PHARM INDUSTRY | 2014-06-04 | — | — | CN | disclosed |
| WO-2014025658-A1 | PYRROLIDINE THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
| US-6528503-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20030013700-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2003-01-16 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002057225-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315141-A1 | Thrombin Inhibitors | F3, F2, F9 | IDO1 3149/4885HTT 2024/4885HIF1A 1482/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | IDO1 30/4885HTT 330/4885HIF1A 2056/4885 |
| US-20030013700-A1 | Thrombin inhibitors | TFPI, PLAT, TFPI2 | IDO1 1438/4885HTT 473/4885HIF1A 1171/4885 |
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | IDO1 2641/4885HTT 1091/4885HIF1A 2482/4885 |
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | IDO1 1670/4885HTT 1138/4885HIF1A 339/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | IDO1 3082/4885HTT 859/4885HIF1A 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.